Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Early Hospital Readmission Following Kidney Re-Transplantation.
E. King, B. Orandi, S. Bae, X. Luo, D. Segev.
Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD.
BACKGROUND: Among first time kideny transplant (KT) recipients the incidence of early hospital readmission (EHR) is 31%. Kidney re-transplants are more complex and we hypothesize…
2016 American Transplant Congress
Seven Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients.
J. Leventhal,¹ J. Galvin,¹ D. Stare,¹ L. Gallon,¹ J. Miller,¹ J. Mathew,¹ M. Abecassis,¹ S. Ildstad.²
¹Northwestern University, Chicago; ²University of Louisville, Louisville.
36 subjects have been enrolled and 31 transplanted in a phase 2 protocol (IDE 13947) to induce tolerance in recipients of living donor renal allografts…
2016 American Transplant Congress
Differential Regulation of the Microvascular Endothelial Cell Mediated Allogeneic CD4+ T Cell Response by Anti-HLA-DR and -DQ Alloantibodies in an Inflammatory Context.
N. Mooney,^1,2 A. Cross,^1,2 J. Lion,^1,2 A. Haziot,^1,2 D. Glotz.^1,2,3
¹INSERM UMRS 1160, Institut Universitaire d'Hématologie, Paris, France; ²Université-Paris-Diderot, Sorbonne Paris Cité, Paris, France; ³Service de Néphrologie et Transplantation, Hôpital Saint Louis, Paris, France.
This study examines the basic mechanisms by which high levels of circulating HLA class II donor-specific-antibodies can contribute to microvasculature damage in chronic antibody mediated…
2016 American Transplant Congress
Who Should Decide? Potential Living Kidney Donor Preferences for Making Decisions About Risk.
C. Thiessen,¹ J. Gannon,¹ K. Kennedy,² D. Dobosz,¹ S. Li,¹ D. Gray,³ A. Mussell,³ E. Gordon,² P. Reese,³ S. Kulkarni.¹
¹Yale U, New Haven; ²Northwestern U, Chicago; ³U Pennyslvania, Philadelphia.
BackgroundTransplant centers debate how to manage risks to potential living kidney donors (LKDs) when there is a lack of consensus about reasonable donor risk .We…
2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
A. Benitez,¹ T. Milford,² K. Torralba,³ K. Payne,² M. De Vera.¹
¹Transplantation Institute, Loma Linda University Health Care, Loma Linda, CA; ²Basic Science Division of Anatomy, Loma Linda University, Loma Linda, CA.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…
2016 American Transplant Congress
Kidney Transplantation in HIV Patients: Effect of Race on the Choice of Anti-Thymocyte Globulin Induction Immunosuppression.
M. Casey, T. Aijaz, X. Wen, S. Rehman, A. Santos, E. Thomas, K. Andreoni, K. Womer.
University of Florida, Gainesville, FL.
Introduction: HIV positive status is a well-known risk factor for acute rejection (AR) in kidney transplant recipients (KTR). In the United States, the majority of…
2016 American Transplant Congress
Post-Transplant Monitoring of Donor-Specific Anti-HLA Antibodies and Their Characteristics Improves Risk Stratification of Kidney Allograft Loss.
D. Viglietti,¹ A. Loupy,² C. Bentlejewski,³ C. Legendre,² D. Glotz,¹ A. Zeevi,³ C. Lefaucheur.¹
¹Saint-Louis Hospital, Paris, France; ²Necker Hospital, Paris, France; ³University of Pittsburgh Medical Center, Pittsburgh.
Circulating donor-specific anti-HLA antibodies (DSA) are associated with allograft failure in solid-organ transplantation. We investigated the pathogenic characteristics of DSA that may improve risk prediction…
2016 American Transplant Congress
Clinical Significance of Non-HLA Antibodies in the Development of Microcirculation Inflammation in Allograft Tissue After Kidney Transplantation.
J. Min,^1,3 H. Lee,^2,3 B. Chung,^1,3 E.-J. Oh,^2,3 C. Yang.^1,3
¹Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ²Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ³Transplant Research Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The aim of our study is to determine the clinical significance of pre-transplant non-HLA antibodies, mainly those targeting the angiotenin II type I receptor (AT1R)…
2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
X. Wen,¹ M. Casey,¹ A. Santos,¹ A. Hartzema,² K. Womer.¹
¹Department of Medicine, University of Florida, Gainesville, FL; ²Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…
2016 American Transplant Congress
Survival Advantage with Older Live Donor Compared to Standard Criteria Deceased Donor Kidney Transplantation in Older Recipients.
P. Abrams, M. Cooper, J. Verbesey, R. Ghasemian, M. Grafals, A. Gilbert, J. Moore, J. Fenton, C. Cannon, J. Rapisurra, B. Javaid.
MedStar Georgetown Transplant Institute, Georgetown University School of Medicine, Washington, DC.
Objective: Analyze post-transplant outcomes in older recipients of kidney transplants from older live donors compared to older recipients of standard criteria deceased donor kidney transplants.Methods:…